Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.
暂无分享,去创建一个
A R Willan | I. Tannock | T. Smith | P. Warde | T. Panzarella | M. Moore | A. Willan | T. Panzarella | M. Krahn | A. Neville | T. Neogi | I F Tannock | P Warde | T J Smith | M J Moore | S. Ernst | T Neogi | M D Krahn | D J Bloomfield | T Panzarella | S Ernst | A Neville | D. Bloomfield
[1] M. Stockler,et al. Resource implications of palliative chemotherapy for ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Denes. Chemotherapy with mitoxantrone in hormone-refractory prostate cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Stearns,et al. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. , 1996, Statistics in medicine.
[4] A R Willan,et al. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. , 1996, Health economics.
[5] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Osoba,et al. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group. , 1996, Journal of the National Cancer Institute. Monographs.
[7] C. Williams,et al. European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care. , 1995, European journal of cancer.
[8] D. Fairclough,et al. Comparison of Time-tradeoff Utilities and Rating Scale Values of Cancer Patients and Their Relatives , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.
[9] A. McEwan,et al. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. , 1994, European urology.
[10] A. Gafni,et al. Discounting in the Economic Evaluation of Health Care Interventions , 1993, Medical care.
[11] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[12] V. Goel,et al. Technology assessment and cost-effectiveness analysis: misguided guidelines? , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[13] A S Detsky,et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[14] P. Warde,et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] I. Tannock,et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[17] G W Torrance,et al. Utility approach to measuring health-related quality of life. , 1987, Journal of chronic diseases.
[18] G. Torrance. Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.
[19] H. Fineberg,et al. Preferences for Health Outcomes , 1984, Medical decision making : an international journal of the Society for Medical Decision Making.
[20] D L Sackett,et al. Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. , 1981, The New England journal of medicine.